Nir Barzilai, MD

Nir Barzilai, MD

The Rennert Chair of Aging Research,
Professor of Medicine and Genetics and
Director, Nathan Shock Center of Excellence in the Biology of Aging, Albert Einstein College of Medicine

The Rennert Chair of Aging Research
Professor of Medicine and Genetics and
Director, Nathan Shock Center of Excellence in the Biology of Aging
Albert Einstein College of Medicine

Dr. Barzilai is a chaired professor of medicine and genetics and director of the biggest center in the world to study the biology of aging. He is the recipient of a National Institutes of Health (NIH) Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are being developed based, in part, on these paradigm-changing studies. He is the recipient of numerous prestigious awards, including the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award.  He is leading the TAME (Targeting/Taming Aging with Metformin) multi-central study to prove the concept that multi-morbidities of aging can be delayed in humans and to change the U.S. Food and Drug Administration (FDA) indications to allow for next generation interventions. He is a founder of CohBar Inc. (now a public company) and medical advisor for Life Biosciences. He is on the boards of AFAR and CohBar. He has been featured in major papers, TV programs and documentaries (TEDx and TEDMED) and has been consulting or presenting the promise for targeting aging at The Singapore Prime Minister’s Office, several International Banks, the Vatican, PepsiCo, Milken Institute, The Economist and Wired Magazine.